News

The company believes the decline in sales is related to customers tumbling their capital expenditures as a result of the changes in the global economy. The anticipated revenue

Since joining 3SBio in October 2008, Mr Tan has been acting as the financial advisor for the company, providing advice on the company’s capital market initiatives and overseeing

Mr Larochelle will remain on the board of directors of Adaltis and will ensure a smooth executive leadership transition, working with Mr Bambic in his new role. Most

The 500mg single-dose vial expands Sagent’s existing line of cefazolin products beyond the 1gm single-dose vials and 10gm pharmacy bulk package vials launched in March 2008. All doses

A division of cancer treatment and diagnosis-sponsored Phase I clinical trial is expected to be initiated to evaluate dose and safety of GDC-0449 in pediatric patients with medulloblastoma.

According to the company, this new system requires no coding, displays results in seven seconds, requires a tiny 0.3 micro liter sample size, and was developed to use

The acquisition gains PPD immediate entry into Romania, Bulgaria, Serbia and Croatia with established infrastructure and expertise, and also bolsters PPD’s existing staff and operations in Poland, Russia

From 1999 through 2009, Dr Brzeczko was vice president of global pharma new product development and pharma technologies for International Specialty Products, a contract services group specializing in

The goal of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750, a patent-protected formulation of hyaluronan. Orcrist utilized the regulatory